Storia in 2 fonti

Biotech M&A is accelerating. Track the deals that are happening here.

Catalyst is already the fourth biotech acquisition this month, continuing an acceleration of bigger-ticket deals that’s put 2026 on a faster pace than every year since at least 2018.

Raccontata da

biopharmadive.com

pharmavoice.com

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

biopharmadive.comStai leggendo3 mesi fa

Biotech M&A is accelerating. Track the deals that are happening here.

Catalyst is already the fourth biotech acquisition this month, continuing an acceleration of bigger-ticket deals that’s put 2026 on a faster pace than every year since at least 2018.

originale

pharmavoice.com3 mesi fa

Lilly, Gilead lead pharma’s M&A boom

Deal volume in 2026 is substantially outpacing last year, and activity is being driven by interest in cancer and autoimmune disease drugs.

Leggi questa versione → originale

Timeline cronologica

giovedì 7 maggio 2026·biopharmadive.com
Biotech M&A is accelerating. Track the deals that are happening here.
Catalyst is already the fourth biotech acquisition this month, continuing an acceleration of bigger-ticket deals that’s put 2026 on a faster pace than every year since at least…
venerdì 8 maggio 2026·pharmavoice.com
Lilly, Gilead lead pharma’s M&A boom
Deal volume in 2026 is substantially outpacing last year, and activity is being driven by interest in cancer and autoimmune disease drugs.